Alimera Sciences has initiated enrollment for its prospective Iluvien study New Day, according to a press release.
The single-masked, randomized, controlled, multicenter study is designed to investigate Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg as a baseline therapy for patients with diabetic macular edema. The trial plans enrollment of about 300 treatment naive or minimally treated patients at more than 40 sites worldwide.
Patients will receive either five injections of intravitreal aflibercept 2 mg at 4-week intervals for 16 weeks as a loading dose or an Iluvien
Uncategorized